To formally test the impact of disrupting peroxisome biogenesis on response to MAPKis, we knocked down PEX3 with siRNAs in 4 human melanoma cell lines harboring different genetic mutations (Figure 1B) to assess whether this would alter their response to MAPK inhibition. The gene discussed is PEX3; the disease is melanoma.